Associate Director, HEOR, Japan

Darum lohnt es sich

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. They will work in concert with Global HEOR and other regional teams to deliver an Integrated Evidence Plan for each asset and disease area.

They will be accountable for delivering value demonstration • Integrated Evidence Planning: Participate within the Revolution Medicines IEP process and ensure the comprehensive plan achieves all needs for the Japan. • Evidence Generation & Analysis: Lead or participate in the development of health economic models (cost‑effectiveness, budget impact), real‑world evidence, burden‑of‑disease assessments, and outcomes research programs that support regulatory filings, HTA submissions, and reimbursement discussions. • Cross‑Functional Collaboration: Partner with Market Access, Medical Affairs, Commercial, Regulatory, and Clinical Development teams to ensure HEOR insights inform decision making across the product lifecycle. • External Engagement: Represent Revolution Medicines in scientific, payer, and HTA forums; engage external stakeholders including key opinion leaders, academic collaborators, HTA bodies, and reimbursement authorities. • Team & Vendor Leadership: Help to lead initiatives both within RevMed and to manage external collaborators (consultants, vendors) to support various HEOR projects within budget and timelines. • Communication: Communicate HEOR strategy, research outcomes, and value propositions to internal leadership (including European and global functions) and external audiences.

Preferred Skills • Demonstrated ability to drive success through cross‑functional teams and external matrices. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers.

The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC‑6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC‑9805), a RAS(ON) G12D‑selective inhibitor; and RMC‑5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.

Opportunity The Associate Director, HEOR Japan will provide execution, and scientific leadership across health economics, outcomes research, and real‑world evidence (RWE) to optimize the value demonstration of Revolution Medicines oncology portfolio across JPAC markets.

The role will align HEOR evidence generation with market access, pricing & reimbursement, patient access strategies, and cross‑functional planning. The Associate Director, HEOR Japan will report to the Executive Medical Director, Japan and a dotted line into the Global HEOR group.

Key Responsibilities • Strategic Leadership: Define, drive and deliver upon a HEOR strategy within Japan in support of product lifecycle planning, value evidence generation, pricing/reimbursement, and access engagements.

Required Skills, Experience and Education • Advanced degree (PhD, MSc, MPH, or equivalent) in Health Economics, Epidemiology, Pharmacoeconomics, Biostatistics, Public Health, or related discipline. • Demonstrated HEOR experience (>5‑7 years) in pharmaceutical/biotech/consulting settings with significant leadership exposure. • Demonstrated success within Japan. • Demonstrated expertise in health economic modeling, RWE study design, outcomes research methodologies, and HTA submission experience. • Strong scientific credibility, strategic vision, and ability to influence cross‑functional and external stakeholders. • Excellent communication and leadership skills with experience presenting at scientific and payer forums. • Fluent communication in English.